Company intelligence / Profile preview
Chengdu Institute of Biological Products
- Ownership
- Private
- Employees
- ~1400
- Development stage
- Other
Overview
CDIBP is one of China's largest research and manufacturing institutes for human vaccines, with WHO-prequalified vaccines (including Japanese Encephalitis, BCG, DTP, and PPV23), significant capacity, and a track record of global supply and collaboration; its products are widely approved and marketed, reaching commercial stage in multiple indications[1][3][6][7][9].
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineBiologicLive attenuated vaccinePolysaccharide vaccineConjugated vaccineMultivalent vaccine
- Industry
- Pharma
Drug pipeline
8 assets7 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Chengdu Institute of Biological Products.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Institute of Biological Products.